The Double Face of Exosomes Derived from Mesenchymal Stromal Cells in Fibrotic Lung Diseases: Pathology Contribution or Treatment?

Abstract

Several studies have attempted to clarify the role of exosomes and/or microvesicles derived from mesenchymal stromal cells (MSCs) (collectively indicated as extracellular vesicles: MSCs-EVs) in pulmonary fibrosis. Depending on their origin and on the micro-environmental context, MSCs-EVs may support or attenuate the fibrotic invasion of the lung, a hallmark of all Interstitial Lung Diseases (ILDs). Indeed, EVs have emerged as pivotal intercellular mediators and their potential diagnostic and therapeutic applications have been suggested. We aim here to elucidate the dual role of MSCs-derived exosomes and microvesicles: the contribution to pulmonary fibrosis progression, exerted by the MSCs-EVs originated from resident MSCs, or the potential therapeutic activity of those generated from healthy MSCs. Actually, MCSs-EVs appear as the frontiers of cell-free therapy and nano-medicine research in a great number of pre-clinical studies, but developments are needed to optimize and standardize their isolation, production and delivery. Interestingly, since the respiratory system directly communicates with the external environment, lung treatment could be approached by MSCs-EVs nebulization as a preferential administration route, integrating targeted pulmonary delivery with an enhanced patient’s compliance. Hence MSCs-EVs may contribute to ILD pathogenesis, display a potential as biomarkers, and still hold promise as therapeutic agents to reduce lung fibrosis. However further researches are needed to validate their clinical application.

Keywords

Interstitial lung disease / Idiopatic pulmonary fibrosis / Mesenchymal stromal cell / Exosomes / Microvescicles

Author Contributions

Conceptualization, D.d.T.; Writing—Original Draft Preparation, D.d.T., P.G.; Writing—Review & Editing, D.d.T., P.G., M.G., E.B.; Visualization, P.G.; Supervision, E.B., D.d.T.

Ethics Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Funding

This work was partially funded by 5X1000 year 2022, grant # C809A (to E.B.).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Althobiani MA, Russell AM, Jacob J, Ranjan Y, Folarin AA, Hurst JR, et al. Interstitial lung disease: A review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front. Med. 2024, 11, 1296890. DOI:10.3389/fmed.2024.1296890

[2] Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319, 1244-1247. DOI:10.1126/science.1153124

[3] Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: Proteomic insights and diagnostic potential. Expert Rev. Proteom. 2009, 6, 267-283. DOI:10.1586/epr.09.17

[4] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659. DOI:10.1038/ncb1596

[5] Dinh PC, Paudel D, Brochu H, Popowski KD, Gracieux MC, Cores J, et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 2020, 11, 1064. DOI:10.1038/s41467-020-14344-7

[6] Lopes-Pacheco M. Extracellular Vesicles: Multimodal Tools for Diagnosis, Prognosis, and Therapy in Respiratory Diseases. Expert Rev. Mol. Med. 2025, 27, e38. DOI:10.1017/erm.2025.10025

[7] Nija RJ, Nithya TG. Pulmonary fibrosis and exosomes: Pathways to treatment. Mol. Biol. Rep. 2025, 52, 749. DOI:10.1007/s11033-025-10855-y

[8] Wang J, Shi Y, Su Y, Pang C, Yang Y, Wang W. Research advances of extracellular vesicles in lung diseases. Cell Transplant. 2025, 34, 9636897251362031. DOI:10.1177/09636897251362031

[9] Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 1987, 262, 9412-9420. DOI:10.1016/S0021-9258(18)48095-7

[10] Martin-Medina A, Lehmann M, Burgy O, Hermann S, Baarsma HA, Wagner DE, et al. Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2018, 198, 1527-1538. DOI:10.1164/rccm.201708-1580OC

[11] Singla A, Reuter S, Taube C, Peters M, Peters K. The molecular mechanisms of remodeling in asthma, COPD and IPF with a special emphasis on the complex role of Wnt5A. Inflamm. Res. 2023, 72, 577-588. DOI:10.1007/s00011-023-01692-5

[12] Zhang X, Liu X, Noble PW. From fibroblast foci to dense scars: PAK2-activated fibroblasts drive fibrosis progression in idiopathic pulmonary fibrosis. Eur. Respir. J. 2025, 66, 2501549. DOI:10.1183/13993003.01549-2025

[13] Kadota T, Yoshioka Y, Fujita Y, Araya J, Minagawa S, Hara H, et al. Extracellular Vesicles from Fibroblasts Induce Epithelial-Cell Senescence in Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 2020, 63, 623-636. DOI:10.1165/rcmb.2020-0002OC

[14] Chanda D, Thannickal VJ. Modeling Fibrosis in Three-Dimensional Organoids Reveals New Epithelial Restraints on Fibroblasts. Am. J. Respir. Cell Mol. Biol. 2019, 61, 556-557. DOI:10.1165/rcmb.2019-0153ED

[15] Burgy O, Mayr CH, Schenesse D, Fousekis Papakonstantinou E, Ballester B, Sengupta A, et al. Fibroblast-derived extracellular vesicles contain SFRP1 and mediate pulmonary fibrosis. JCI Insight 2024, 9, e168889. DOI:10.1172/jci.insight.168889

[16] Mayr CH, Sengupta A, Asgharpour S, Ansari M, Pestoni JC, Ogar P, et al. Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts. Eur. Respir. J. 2024, 63, 2301326. DOI:10.1183/13993003.01326-2023

[17] Czyzak B, Majewski S. Concomitant Idiopathic Pulmonary Fibrosis and Lung Cancer: An Updated Narrative Review. Adv. Respir. Med. 2025, 93, 31. DOI:10.3390/arm93040031

[18] Fujita Y, Fujimoto S, Miyamoto A, Kaneko R, Kadota T, Watanabe N, et al. Fibroblast-derived Extracellular Vesicles Induce Lung Cancer Progression in the Idiopathic Pulmonary Fibrosis Microenvironment. Am. J. Respir. Cell Mol. Biol. 2023, 69, 34-44. DOI:10.1165/rcmb.2022-0253OC

[19] Lei Y, Zhong C, Zhang J, Zheng Q, Xu Y, Li Z, et al. Senescent lung fibroblasts in idiopathic pulmonary fibrosis facilitate non-small cell lung cancer progression by secreting exosomal MMP1. Oncogene 2025, 44, 769-781. DOI:10.1038/s41388-024-03236-5

[20] Njock MS, Guiot J, Henket MA, Nivelles O, Thiry M, Dequiedt F, et al. Sputum exosomes: Promising biomarkers for idiopathic pulmonary fibrosis. Thorax 2019, 74, 309-312. DOI:10.1136/thoraxjnl-2018-211897

[21] d’Alessandro M, Gangi S, Soccio P, Canto E, Osuna-Gomez R, Bergantini L, et al. The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study. Int. J. Mol. Sci. 2023, 24, 4071. DOI:10.3390/ijms24044071

[22] Suchankova M, Zsemlye E, Urban J, Barath P, Kohutova L, Sivakova B, et al. The bronchoalveolar lavage fluid CD44 as a marker for pulmonary fibrosis in diffuse parenchymal lung diseases. Front. Immunol. 2024, 15, 1479458. DOI:10.3389/fimmu.2024.1479458

[23] Curley GF, O’Kane CM, McAuley DF, Matthay MA, Laffey JG. Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now? Am. J. Respir. Crit. Care Med. 2024, 209, 789-797. DOI:10.1164/rccm.202311-2046CP

[24] Ting AE, Baker EK, Champagne J, Desai TJ, Dos Santos CC, Heijink IH, et al. Proceedings of the ISCT scientific signature series symposium, “Advances in cell and gene therapies for lung diseases and critical illnesses”. International Society for Cell & Gene Therapy, Burlington VT, US, July 16, 2021. Cytotherapy 2022, 24, 774-788. DOI:10.1016/j.jcyt.2021.11.007

[25] Weiss DJ. Unraveling the Complexities of Mesenchymal Stromal Cell-based Therapies: One Size Doesn’t Fit All. Am. J. Respir. Crit. Care Med. 2024, 210, 709-711. DOI:10.1164/rccm.202405-0961ED

[26] Cyr-Depauw C, Cook DP, Mizik I, Lesage F, Vadivel A, Renesme L, et al. Single-Cell RNA Sequencing Reveals Repair Features of Human Umbilical Cord Mesenchymal Stromal Cells. Am. J. Respir. Crit. Care Med. 2024, 210, 814-827. DOI:10.1164/rccm.202310-1975OC

[27] Wang Q, Li J, Wang S, Deng Q, Wang K, Dai X, et al. Single-cell transcriptome profiling reveals molecular heterogeneity in human umbilical cord tissue and culture-expanded mesenchymal stem cells. FEBS J. 2021, 288, 5311-5330. DOI:10.1111/febs.15834

[28] Wang LL, Ouyang MY, Yang ZE, Xing SN, Zhao S, Yu HY. Mesenchymal stem cells-derived exosomes alleviate radiation induced pulmonary fibrosis by inhibiting the protein kinase B/nuclear factor kappa B pathway. World J. Stem Cells 2025, 17, 106488. DOI:10.4252/wjsc.v17.i6.106488

[29] Chen W, Peng J, Tang X, Ouyang S. MSC-derived exosome ameliorates pulmonary fibrosis by modulating NOD 1/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Heliyon 2025, 11, e41436. DOI:10.1016/j.heliyon.2024.e41436

[30] Bertolotto M, de Totero D, Giannoni P, Barisione E, Grosso M, Nano E, et al. Fibroblast-driven MMP-9/TIMP-1 imbalance in bronchoalveolar lavage reflects fibrotic progression in interstitial lung disease. Eur. J. Clin. Investig. 2025, 56, e70162. DOI:10.1111/eci.70162

[31] Charoenphannathon JS, Wong PD, Royce SG, Jaffar J, Westall GP, Wang C, et al. Human bone marrow mesenchymal stem cell-derived extracellular vesicles induce inverse dose-dependent anti-fibrotic effects in human myofibroblast cultures and bleomycin-injured mice with pulmonary fibrosis. Biomed. Pharmacother. 2025, 190, 118370. DOI:10.1016/j.biopha.2025.118370

[32] Chen Y, Li M, Yang J, Chen Y, Wang J. Engineerable mesenchymal stem cell-derived extracellular vesicles as promising therapeutic strategies for pulmonary fibrosis. Stem Cell Res. Ther. 2025, 16, 367. DOI:10.1186/s13287-025-04490-4

[33] Zhou J, Lin Y, Kang X, Liu Z, Zhang W, Xu F. microRNA-186 in extracellular vesicles from bone marrow mesenchymal stem cells alleviates idiopathic pulmonary fibrosis via interaction with SOX4 and DKK1. Stem Cell Res. Ther. 2021, 12, 96. DOI:10.1186/s13287-020-02083-x

[34] Wan X, Chen S, Fang Y, Zuo W, Cui J, Xie S. Mesenchymal stem cell-derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRNA-29b-3p in idiopathic pulmonary fibrosis. J. Cell. Physiol. 2020, 235, 8613-8625. DOI:10.1002/jcp.29706

[35] Sumiyoshi I, Togo S, Watanabe J, Kaneko I, Uzu S, Yonekura T, et al. MicroRNA-4516 in extracellular vesicles-derived mesenchymal stem cells suppressed integrin alphaV-mediated lung fibrosis. Stem Cell Res. Ther. 2025, 16, 442. DOI:10.1186/s13287-025-04559-0

[36] Rosa I, Romano E, Fioretto BS, Manetti M. Pathophysiologic implications and therapeutic potentials of telocytes in multiorgan fibrosis. Curr. Opin. Rheumatol. 2026, 38, 26-37. DOI:10.1097/BOR.0000000000001116

[37] Babadag S, Altundag-Erdogan O, Akkaya-Ulum YZ, Celebi-Saltik B. Evaluation of Tumorigenic Properties of MDA-MB-231 Cancer Stem Cells Cocultured with Telocytes and Telocyte-Derived Mitochondria Following miR-146a Inhibition. DNA Cell Biol. 2024, 43, 341-352. DOI:10.1089/dna.2024.0031

[38] Shi L, Dong N, Chen C, Wang X. Potential roles of telocytes in lung diseases. Semin. Cell Dev. Biol. 2016, 55, 31-39. DOI:10.1016/j.semcdb.2016.02.008

[39] Wei XJ, Chen TQ, Yang XJ. Telocytes in Fibrosis Diseases: From Current Findings to Future Clinical Perspectives. Cell Transplant. 2022, 31, 9636897221105252. DOI:10.1177/09636897221105252

[40] Zheng Y, Cretoiu D, Yan G, Cretoiu SM, Popescu LM, Wang X. Comparative proteomic analysis of human lung telocytes with fibroblasts. J. Cell. Mol. Med. 2014, 18, 568-589. DOI:10.1111/jcmm.12290

[41] Ma R, Wu P, Shi Q, Song D, Fang H. Telocytes promote VEGF expression and alleviate ventilator-induced lung injury in mice. Acta Biochim. Et Biophys. Sin. 2018, 50, 817-825. DOI:10.1093/abbs/gmy066

[42] Zhang S, Sun L, Chen B, Lin S, Gu J, Tan L, et al. Telocytes protect against lung tissue fibrosis through hexokinase 2-dependent pathway by secreting hepatocyte growth factor. Clin. Exp. Pharmacol. Physiol. 2023, 50, 964-972. DOI:10.1111/1440-1681.13823

[43] Gao R, Zhang X, Ju H, Zhou Y, Yin L, Yang L, et al. Telocyte-derived exosomes promote angiogenesis and alleviate acute respiratory distress syndrome via JAK/STAT-miR-221-E2F2 axis. Mol. Biomed. 2025, 6, 21. DOI:10.1186/s43556-025-00259-6

[44] Zou Y, Zhou Y, Li G, Dong Y, Hu S. Clinical applications of extracellular vesicles: Recent advances and emerging trends. Front. Bioeng. Biotechnol. 2025, 13, 1671963. DOI:10.3389/fbioe.2025.1671963

[45] Li M, Huang H, Wei X, Li H, Li J, Xie B, et al. Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment. Signal Transduct. Target. Ther. 2025, 10, 179. DOI:10.1038/s41392-025-02262-3

[46] Isaac R, Reis FCG, Ying W, Olefsky JM. Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab. 2021, 33, 1744-1762. DOI:10.1016/j.cmet.2021.08.006

[47] O’Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat. Rev. Mol. Cell Biol. 2020, 21, 585-606. DOI:10.1038/s41580-020-0251-y

[48] Zhang J, Li S, Li L, Li M, Guo C, Yao J, et al. Exosome and exosomal microRNA: Trafficking, sorting, and function. Genom. Proteom. Bioinform. 2015, 13, 17-24. DOI:10.1016/j.gpb.2015.02.001

[49] Hagey DW, Ojansivu M, Bostancioglu BR, Saher O, Bost JP, Gustafsson MO, et al. The cellular response to extracellular vesicles is dependent on their cell source and dose. Sci. Adv. 2023, 9, eadh1168. DOI:10.1126/sciadv.adh1168

[50] Maumus M, Rozier P, Boulestreau J, Jorgensen C, Noel D. Mesenchymal Stem Cell-Derived Extracellular Vesicles: Opportunities and Challenges for Clinical Translation. Front. Bioeng. Biotechnol. 2020, 8, 997. DOI:10.3389/fbioe.2020.00997